Company profile: Antibe Therapeutics
1.1 - Company Overview
Company description
- Provider of novel anti-inflammatory drugs that improve existing, proven therapies, targeting diseases characterized by inflammation, pain, and vascular dysfunction. Offers a proprietary hydrogen sulfide platform; pipeline includes Otenaproxesul for acute pain with demonstrated gastrointestinal safety and efficacy in chronic pain, ATB-352 for specialized pain, and a program for mild-to-moderate inflammatory bowel disease.
Products and services
- Hydrogen Sulfide Platform: A proprietary platform that leverages hydrogen sulfide’s therapeutic potential to create improved versions of existing anti-inflammatory drugs for inflammation, pain, and vascular dysfunction applications
- Otenaproxesul: A clinical-stage drug engineered as a safer alternative to opioids and NSAIDs for acute pain, demonstrating gastrointestinal safety and efficacy in chronic pain
- ATB-352: A pipeline analgesic targeting a specialized pain indication, architected to be non-addictive with minimal gastrointestinal damage
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Antibe Therapeutics
Gilead
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for critical diseases, discovering, developing, manufacturing and commercializing treatments across virology, oncology and inflammation. Portfolio includes Biktarvy and Descovy for HIV-1 (treatment and PrEP) and Epclusa for HCV, with efforts to transform viral diseases into manageable conditions and expand access to care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gilead company profile →
LP Pharmaceuticals
HQ: China
Website
- Description: Provider of pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LP Pharmaceuticals company profile →
Futura Medical
HQ: United Kingdom
Website
- Description: Provider of proprietary transdermal solutions. Products include Eroxon, a topical gel for erectile dysfunction that helps men achieve an erection within 10 minutes without a prescription, and DermaSys, a patented platform for delivering treatments via the skin tailored to specific therapeutic indications and desired speed of onset and duration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Futura Medical company profile →
Harvard Apparatus Regenerative Technology
HQ: United States
Website
- Description: Provider of regenerative implant technologies using Cellspan scaffolds seeded with patients’ stem cells, including esophageal and bronchial implants to repair tubular structures and reduce complications; applications for digestive tract disorders and patch technologies for reproductive tract disorders; and a consumer medicine division offering longevity products for Asia’s aging population.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Harvard Apparatus Regenerative Technology company profile →
Arena Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on cardiovascular, central nervous system, inflammatory, and metabolic diseases, including the development of lorcaserin hydrochloride, which has reported positive clinical trial data. Headquartered in San Diego, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arena Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Antibe Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Antibe Therapeutics
2.2 - Growth funds investing in similar companies to Antibe Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Antibe Therapeutics
4.2 - Public trading comparable groups for Antibe Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →